- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02604082
Comparison of Three Technical Airway Clearance in Mechanical Ventilated Patients (ClearanceMV)
November 11, 2015 updated by: Hospital de Clinicas de Porto Alegre
Randomized clinical trial, conducted in the Intensive Care Unit of the Hospital de Clinicas de Porto Alegre from october 2011 until november 2015 .
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Objective: To compare the effectiveness of techniques: vibrocompression (G1), hyperinflation with mechanical ventilation (G2) vibrocompression + hyperinflation with mechanical ventilation (G3) in the amount of aspirated secretions, mechanical ventilator time, incidence of ventilator-associated pneumonia , reintubation tracheal and mortality in mechanical ventilator.
Primary outcome: weight in grams of the aspirated secretions.
Secondary outcome: hemodynamic and pulmonary parameters: heart rate, respiratory rate, mean arterial pressure, peripheral arterial oxygen saturation; peak inspiratory pressure, tidal volume; dynamic compliance ; mechanical ventilator time; reintubation tracheal; Incidence of ventilator-associated pneumonia and mortality in mechanical ventilator.
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- In mechanical ventilation for a period of 24-72 h
- End-expiratory pressure (PEEP) lower 10 cm of water.
- Lower noradrenaline doses of 0.5mg / kg / minute for an average greater than or equal blood outstrips 60 mmHg.
Exclusion Criteria:
- Pneumothorax and hemothorax undrained
- Subcutaneous emphysema
- Osteoporosis
- Acute respiratory distress syndrome - (ARDS)
- Fractures of ribs
- Obese ( BMI greater than 35)
- Mechanical ventilator with higher peak pressures 40 cm of water.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vibocompression (VB)
Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation.
Through the thoracic compression during expiration
|
Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
Other Names:
|
Active Comparator: Hyperinflation (HMV)
Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation.
Through the increase in inspiratory pressure ventilator .
|
Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
Other Names:
|
Experimental: HMV+VB
Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation.
Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
|
Association between Vibrocompression and Hyperinflation with mechanical ventilator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Weight in grams of the pulmonary secretions
Time Frame: up to 24 weeks.
|
up to 24 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time mechanical ventilator (MV) in days
Time Frame: Through study completion, an average of 3 years.
|
Through study completion, an average of 3 years.
|
Reintubation tracheal in percentage in the last 24 hours
Time Frame: Through study completion, an average of 3 years.
|
Through study completion, an average of 3 years.
|
Incidence of ventilator-associated pneumonia in percentage
Time Frame: Through study completion, an average of 3 years.
|
Through study completion, an average of 3 years.
|
Mortality in the MV in percentage
Time Frame: Through study completion, an average of 3 years.
|
Through study completion, an average of 3 years.
|
Heart Rate
Time Frame: up to 24 weeks.
|
up to 24 weeks.
|
Respiratory frequency
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Peripheral oxygen saturation in percentage
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Tidal volume in milliliters
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Peak inspiratory pressure in centimeters of water
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Silvia R Rios Vieira, Dr, HCPorto Alegre, Rio Grande do Sul - Brazil
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
November 6, 2015
First Submitted That Met QC Criteria
November 11, 2015
First Posted (Estimate)
November 13, 2015
Study Record Updates
Last Update Posted (Estimate)
November 13, 2015
Last Update Submitted That Met QC Criteria
November 11, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- 11-0367
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Physical Disability
-
University of Alabama at BirminghamRecruitingDisability Physical | Physical InactivityUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedPhysical Activity | Physical DisabilityFrance
-
Washington University School of MedicineRecruitingPhysical DisabilityUnited States
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of Alabama at BirminghamRecruiting
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RecruitingDisability PhysicalUnited States
-
Washington University School of MedicineNational Institute on Disability, Independent Living, and Rehabilitation...Active, not recruiting
-
University of MichiganEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedDisability PhysicalUnited States
-
University of Colorado, DenverCompletedPhysical DisabilityUnited States
-
University of Alabama at BirminghamNational Institute on Disability, Independent Living, and Rehabilitation...Completed
Clinical Trials on Vibrocompression (VB)
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedPsoriasisGermany, Israel, Poland, Spain
-
Federal University of UberlandiaCompleted
-
Vyome Therapeutics Inc.UnknownAcne VulgarisUnited States
-
ViscofanMinisterio de Ciencia e Innovación, SpainUnknownHeart Failure With Reduced Ejection FractionSpain
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsUnknownAdvanced and/or Metastatic Solid Organ CancerUnited States
-
Priscilla Hsue, MDUniversity of California, Los Angeles; University of UtahWithdrawnHIV Infection | Inflammation | Cardiovascular DiseaseUnited States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedActive Plaque PsoriasisUnited States, Germany, Israel
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedUlcerative ColitisPoland, Bulgaria, Hungary
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedBiomarkerUnited Kingdom
-
Case Comprehensive Cancer CenterWithdrawnProstate CancerUnited States